Atherosclerosis is the primary pathological foundation that underlies the acute cardiovascular and cerebrovascular events, including heart attack and stroke. The iconic feature of atherosclerosis is the plaques formed within the arterial wall, due to the accumulation of cholesterol ester-loaden macrophages, inflammation-induced cell apoptosis, and the formation of necrotic core. The most current clinical therapies are based on lipid-lowering drugs and anti-inflammatory agents, which has shown relatively effective to inhibit the atherosclerotic advancement and can even reverse their progression in the early phase. However, the efficacy of these conventional treatments for advanced atherosclerosis is not always effective, and plaques still existed in the blood vessel will pose a persistent and residual risk for occurrence and/or recurrence of acute coronary heart diseases. Since the first cancer nanomedicine approved by the Food and Drug Administration (FDA) in 1995, nanomedicine-based therapeutics have made a tremendous progress in cancer therapy. Recently, the nanomedicine has expanded into the realm of vascular diseases, such as atherosclerosis. The use of nanoparticles has emerged an important platform for the prevention and treatment of advanced atherosclerosis, thus reducing the risk of cardiovascular events. Although there is no FDA approval granted for nanomedicine in atherosclerosis up to now, the feasibility and safety of nanoparticle-based targeted nanomedicines for atherosclerosis has already been established and confirmed in a larger number of preclinical trails. Understanding those latest advances and clinical challenges of atherosclerosis nanomedicine is urgently required to develop novel nanomedicines to treat atherosclerosis.
The goal of this Research Topic is to provide a forum for scientists from different disciplines to discuss opportunities and challenges in nanomedicine for atherosclerosis to together advance research towards clinical translation.
We welcome submissions related to the nanoparticle-based therapy against atherosclerosis. The following subtopics are included, but are not limited to:
• Identifying new therapeutic targets and drugs for atherosclerosis
• Optimized existing therapies with advanced approaches like nanotechnology, targeted drug delivery and novel drug delivery device
• Novel targeted molecular imaging modalities for accurate detection of atherosclerosis
The Research Topic welcomes Original Research Articles, Review Articles and Case Reports.
Atherosclerosis is the primary pathological foundation that underlies the acute cardiovascular and cerebrovascular events, including heart attack and stroke. The iconic feature of atherosclerosis is the plaques formed within the arterial wall, due to the accumulation of cholesterol ester-loaden macrophages, inflammation-induced cell apoptosis, and the formation of necrotic core. The most current clinical therapies are based on lipid-lowering drugs and anti-inflammatory agents, which has shown relatively effective to inhibit the atherosclerotic advancement and can even reverse their progression in the early phase. However, the efficacy of these conventional treatments for advanced atherosclerosis is not always effective, and plaques still existed in the blood vessel will pose a persistent and residual risk for occurrence and/or recurrence of acute coronary heart diseases. Since the first cancer nanomedicine approved by the Food and Drug Administration (FDA) in 1995, nanomedicine-based therapeutics have made a tremendous progress in cancer therapy. Recently, the nanomedicine has expanded into the realm of vascular diseases, such as atherosclerosis. The use of nanoparticles has emerged an important platform for the prevention and treatment of advanced atherosclerosis, thus reducing the risk of cardiovascular events. Although there is no FDA approval granted for nanomedicine in atherosclerosis up to now, the feasibility and safety of nanoparticle-based targeted nanomedicines for atherosclerosis has already been established and confirmed in a larger number of preclinical trails. Understanding those latest advances and clinical challenges of atherosclerosis nanomedicine is urgently required to develop novel nanomedicines to treat atherosclerosis.
The goal of this Research Topic is to provide a forum for scientists from different disciplines to discuss opportunities and challenges in nanomedicine for atherosclerosis to together advance research towards clinical translation.
We welcome submissions related to the nanoparticle-based therapy against atherosclerosis. The following subtopics are included, but are not limited to:
• Identifying new therapeutic targets and drugs for atherosclerosis
• Optimized existing therapies with advanced approaches like nanotechnology, targeted drug delivery and novel drug delivery device
• Novel targeted molecular imaging modalities for accurate detection of atherosclerosis
The Research Topic welcomes Original Research Articles, Review Articles and Case Reports.
